All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-YC0794 | Anti-TFDP2 (BC-2) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | Human | BC-2 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC0795 | Anti-TFDP2 (D-11) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | Human | D-11 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC0796 | Anti-TFDP2 (TFD5I455) h(scFv-41BB-CD3ζ) CAR, pCDCAR1 | TFD5I455 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |||
CAR-YC1694 | Anti-TFDP2 (BC-2) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | Human | BC-2 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC1695 | Anti-TFDP2 (D-11) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | Human | D-11 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-YC1696 | Anti-TFDP2 (TFD5I455) h(scFv-CD28-CD3ζ) CAR, pCDCAR1 | TFD5I455 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |||
CAR-YJ253 | Anti-TFDP2 (2E6) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 2E6 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YJ448 | Anti-TFDP2 (TFD5I455) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | TFD5I455 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-YJ753 | Anti-TFDP2 (2E6) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2E6 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-YJ948 | Anti-TFDP2 (TFD5I455) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | TFD5I455 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION